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Artificial Genetically Encoded Peptides and Proteins as Next-Generation Therapeutics: Selection of 
ligands for Mycobacterium tuberculosis UDP-Galactopyranose Mutase as Potential Inhibitors. 
Trisha Ghosh 
 
Peptides and small proteins provide a dynamic platform for drug discovery and therapeutics.  They 
have a wide range of applications including inhibition of protein-protein interaction, inhibition of transporter 
and enzyme activity, imaging, and as co-crystallisation ligand for structural studies. In this study, we employed 
in vitro selection of ligands, using mRNA display, from an artificial genetically encoded library of 
peptides/proteins to identify candidates that bind the enzyme Mycobacterium tuberculosis UDP-
Galactopyranose mutase (MtUGM). The enzyme catalyzes the reversible conversion of UDP-galactopyranose 
(UDP-Galp) to UDP-galactofuranose (UDP-Galf), which is then assembled as the galactofuran layer in 
Mycobacterium tuberculosis (Mtb) cell wall. Cell wall biosynthesis is essential for Mtb survival and 
pathogenicity, deletion in genes involved in this process have proven lethal. We successfully identified 
macrocyclic peptides (MCPs) and affibodies specific for MtUGM from a library with a diversity >1012 clones 
through random non-standard peptide integrated discovery (RaPID) system and mRNA display, respectively. 
Enrichment of positive binders was observed for both selection processes suggesting binding specificity. 
Previous studies reveal that natural product-like MCPs can inhibit enzyme activity; their small size, 
conformational stability and high affinity for the target makes them attractive ligands. Thus, we hypothesize 
that identified MCPs may show inhibition of MtUGM thereby halting cell wall biosynthesis. Discovered 
affibodies will be used for structural analysis of MtUGM. The World Health Organisation (WHO) reported 
tuberculosis (TB) caused by Mtb to be one of the leading causes of death worldwide, with increasing incidences 
of drug resistant strains necessitating discovery of novel therapeutics. Through our study, we present a novel 
approach for discovering peptide/protein-based ligands for MtUGM and hope to develop an assay for 
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Tuberculosis and Current Treatment 
 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It remains the 
leading cause of death from a single infectious agent. In 2018, approximately 10 million people in total 
were diagnosed with TB of which 1.5 million cases were fatal [1]. TB is primarily a pulmonary disease, 
affecting the lungs, but it can be extrapulmonary affecting other parts of the body [2, 6]. M. tuberculosis 
spreads from an affected individual to another in the form of aerosol droplets. The virulent bacteria are 
phagocytosed by macrophage cells in the alveoli via macrophage mannose receptors [3]. Upon entry into 
the host macrophage, the bacteria reside in phagosomes and escapes degradation by inhibiting phagosome-
lysosome fusion [4]. Studies have shown that infected macrophages in the lung, through their production 
of chemokines, cause an immune response.  Inactivated monocytes, lymphocytes, and neutrophils form a 
granulomatous lesion to contain the spread of infection. Active pulmonary TB is the stage when the bacteria 
escapes this granuloma stage and spread in the lung tissue; it can also spread to other tissues via lymphatic 
vessels and blood resulting in extrapulmonary TB [5, 6]. 
A combination of chemotherapeutic agents is administered for six months as first line drugs for treating 
active TB. This includes mainly four drugs- isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and 
ethambutol (EMB) prescribed for an initial 2-month phase followed by a continuation phase with INH and 
RIF for 4 months [7]. In the past decade, a rise in cases of multiple drug resistant-TB (MDR-TB) caused 
by strains of M. tuberculosis resistant to both rifampicin and isoniazid with or without resistance to other 
drugs has been reported. Total drug resistant-TB (TDR-TB) is caused by strains that are resistant to all the 
four first line drugs [8, 9]. At this stage second line of drugs are prescribed, this mainly includes 
aminoglycosides, cycloserine (analogue of D-alanine) and fluoroquinolones. These drugs are less effective 
than the first-line drugs (e.g., p-aminosalicylic acid); or may have toxic side-effects (e.g., cycloserine). 
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Extensively drug resistant TB (XDRTB) is a rare type of MDR-TB, which is resistant to both RIF and INH, 
in addition to any fluoroquinolone and at least one of three second line drugs [10]. Demographic data shows 
that treatment success rate varies with respect to strain, country, and the method of treatment. As of 2018, 
the success rate for non-resistant strain has been 85% using first line drugs, however, it is >70% for MDR-
TB/TDR-TB in developed countries and as low as 56% in developing countries [11]. The rapid evolution 
of bacteria leading to resistance against anti-TB drugs poses a challenge to the community to develop an 
effective drug regimen [12]. This necessitates the discovery of novel therapeutics that will increase the 
efficacy of existing drugs, promise administration at a lower dosage, fewer side effects and overcome drug 
resistance.  
 
1.2 Mycobacterium Cell Wall Biosynthesis and The Role of MtUGM 
 
M. tuberculosis is a facultative intracellular pathogen with the ability to infect and live in the host for 
decades, as in the case of latent TB, despite a functioning host immune system [13]. The success of this 
pathogen has been associated with the complex structure of the cell envelope, which is credited for the 
bacteria’s virulence and antibiotic resistance [14]. The currently administered first line drugs target the 
process of cell wall biosynthesis, elucidating the importance of cell wall for the survival of the bacteria. 
INH inhibits mycolic acid elongation, PZA inhibits fatty acid synthase, and EMB affect the arabinan 
assembly (Fig 1) [15]. However, the bacteria have evolved to escape drug action either by mutating its 
native enzymes which are drug targets, increasing drug efflux or creating low permeability to the drug [16]. 
Nonetheless, the cell wall remains to be an attractive target for drug development.  
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Figure 1.  Anti-TB drugs targeting enzymes involved in cell wall biosynthesis. Arabinosyl transferase is 
inhibited by Ethambutol, further disrupting the arabinan assembly. Pyrazinamide and Isoniazid obstructs 
lipid chain formation by inhibiting fatty acid synthase I and II respectively. However, resistant Mtb strains 
reported mutations in these target enzymes to escape drug binding. 
 
The cell wall is thick, waxy and hydrophobic. The structural complexity of cell wall—formed by 
peptidoglycan, lipid mycolic acid, and polysaccharide arabinogalactan—makes mycobacterium unique. 
Arabinogalactan (AG) is a heteropolysaccharide that is covalently linked to muramic acid residues of 
peptidoglycan by a phosphodiester bond [17, 18]. It is comprised of arabinose and galactose sugars that are 
present in the furanose ring form, D-galactofuranosyl (Galf) and D-arabinofuranosyl (Araf). The galactan 
layer is linear, with alternating β-(1→5) and β-(1→6) glycosidic linkages (5-linked β-D-Galf and 6-linked 
β-D-Galf residues). Previous studies have identified three key enzymes—UGM, GlfT1 and GlfT2—that 
help in galactan biosynthesis. UDP galactopyranose mutase (UGM), converts UDP-galactopyranose (UDP-
Galp; the nucleotide sugar donor of the six-membered ring form of galactose) to UDP-galactofuranose 
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(UDP-Galf). The galactofuranosyltransferases GlfT1 and GlfT2, respectively prime and elongate the 
alternating β-(1→5) and β-(1→6) galactan using the UDP-Galf donor substrate and a glycan acceptor 
substrate (Fig 2) [19-24]. UGM is found in several pathogens including bacteria, fungi, and nematodes. 
However, it is not found in mammals making it an attractive drug target [25, 26]. Efforts towards finding 
inhibitors for UGM have shown promising results. Inhibitors designed against UGM were essentially 
substrate analogs, some resembling UDP-Galf which binds to the active site of the enzyme [27, 28].  
 
Figure 2. Role of UDP-Galactopyranose mutase in cell wall biosynthesis. UGM catalyzes the 
interconversion of UDP-Galp and UDP-Galf. Glft1 and Glft2 prime and elongate the alternating β-(1→5) 
and β-(1→6) galactan using the UDP-Galf donor substrate and a glycan acceptor substrate to synthesize 




Figure 3. Mycobacterium tuberculosis cell wall structure. It has a unique structure, it is composed of 




1.3 Peptide/protein-based Therapeutics 
 
Peptides and proteins are made of amino acids connected with peptide bonds; they are 2-50 amino acids 
and >50 amino acid in length, respectively. They are a dynamic class of biomolecules with a wide range of 
applications with respect to drug discovery and therapeutics [29]. In biological systems proteins are notable 
for their ligand specific binding, for example, enzyme reactions, receptor binding and signaling. They can 
form specific chemical interactions with other proteins or ligands; therefore, they are of high interest with 
respect to drug development [30]. Protein based therapeutics, commonly called as ‘biologics’ have 
advanced leaps and bounds since the introduction of insulin therapy in 1920s [31]. Ensuing developments 
in protein expression, purification, and chemical synthesis; progress in peptide/protein-based therapies have 
been observed with successful drugs reaching the market. This includes growth factors, hormones, 
engineered antibodies and synthetic peptide drugs (oxytocin, vasopressin) [32] commercialized in the 1980s 
[33]. During this time, the primary method for discovering bioactive peptides relied on screening natural 
product libraries. However, naturally occurring peptides may not be suitable for direct administration 
because of its physical and chemical instability. Nonetheless, we see have witnessed research and the use 
of peptide-based drugs for addressing various diseases overt the past two decades [29].  
Initial studies in peptides as therapeutics agents against pathogenic diseases started with the discovery of 
naturally occurring antimicrobial peptides (AMPs) [34]. Also known as host defense peptides (HDPs), these 
are endogenous peptides produced by different organisms including plants, fungi, animals, humans and 
microbes, against pathogenic infection. AMPs have been widely studied for their antimicrobial properties. 
AMPs also have anticancer, antifungal, and antiviral activity [35-37]. AMPs have exhibited many 
advantages over classical antibiotics, for example they are less likely to initiate drug resistance and they 
have a synergistic effect when used in combination with existing antibiotic drugs. Regardless of these 
advantages, not many naturally occurring AMPs have made it to market [38]. Of various structures of AMPs 
reported, most of the successful antibiotics have a cyclic structure, which indicates the importance of 
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macrocycles in peptide bioactivity [39]. Macrocyclic peptides (MCPs) also make up a major class of 
peptide-based antibiotic drugs. 
Though, peptides are comparatively easy to design and synthesize, larger molecules like proteins have also 
served as therapeutic agents [40]. Antibodies are widely studied proteins with therapeutic effects, however, 
their large structure (>50 kDa) presents limitations, hindering cell penetration [41-43]. They are surface 
binders, thus engineering antibodies for small the catalytic grooves of enzyme active site are difficult. 
Moreover, most require post-translation modifications making the production process difficult and 
expensive. As a result, smaller antibody-like molecules were required to overcome said limitations [42, 44]. 
Rational design approaches have been adapted based on the ligand binding domains of antibodies to design 
libraries of novel proteins with similar scaffolds or structures. Some examples include, nanobodies (12-15 
kDa) known as single domain antibody (variable domain of the heavy chain); monobodies, synthetic 
proteins much smaller (10 kDa) than antibodies were engineered based on fibronectin III domain; affibodies 
(<7 kDa), engineered from Z domain of SPA [45-48]. These engineered proteins have been studied in a 
variety of contexts, from probing and imaging to inhibiting enzymes, thus, providing an array of libraries. 
 
1.3.1 Macrocyclic Peptides as Potential Inhibitors 
 
The discovery of macrocyclic peptide-based natural products has led scientists to explore MCPs as 
drug candidates and scaffolds. The naturally occurring MCPs form a diverse family of peptides found 
within a range of organisms such as bacteria, fungi, plants, and mammals [49]. These peptides consist of 
non-standard amino acids and modified side chains. Cyclosporin A, an immunosuppressant drug, is one 
such example, extracted from an ascomycete fungus Tolypocladium inflatum Gams [50-53]. The 
macrocyclic backbone imparts structural rigidity and often possess modifications such as N-methylation. 
This increases cell permeability and provides resistance to protease [49, 54]. Among potent biologically 
active peptides, macrocyclization can occur in a variety of modes, including head to tail cyclisation (Fig 
18 
 
4a), formation of multiple macrocycles (Fig 4b), as well as the formation of macrocyclic head with a linear 




Figure 4.  Naturally occurring functional MCP: a. Cyclosporin A isolated from the fungus Tolypocladium 
inflatum; used as immunosuppressant drug b. Vancomycin is a glycopeptide antibiotic produced by the 
soil bacterium Amycolatopsis orientalis c. Daptomycin is a lipopeptide antibiotic used against Gram-
positive bacteria isolated from Streptomyces roseosporus d. Etamycin A, antibiotic first discovered in 




MCPs have been shown to have favorable pharmacological properties compared to standard linear peptides. 
They are metabolically stable, target-specific, and have high affinity with the ability to modulate protein-
protein interactions. These properties make MCPs excellent drug candidates [55, 88]. Traditional 
approaches in the discovery of antibiotics have mainly involved phenotypic screening of natural 
compounds. Naturally occurring peptides with macrocyclic structures represents a class of successful 
antibiotic drugs which includes compounds such as Vancomycin, Etamycin A and Daptomycin, (Fig 4) 
[56-58]. Thus, peptide-based macrocycles have been an inspiration for developing novel antibiotics. 
Scientists have explored macrocyclization of oligopeptide libraries to improve their bioactivity. In the early 
nineties, with the advent of high-throughput screening (HTS) of large compound libraries paved the way 
for screening MCP libraries [59, 60]. Subsequent developments in target-specific drug design has directed 
discoveries of MCPs binding to distinct targets. Advances in HTS enabled de novo screening of functional 
peptides. Phage display was the earliest techniques used to generate peptide libraries coupled with chemical 
cyclisation steps [61]. Ribosomal synthesis is carried out in E. coli transduced by phage that contains genes 
for coat proteins fused to randomized peptide. Cyclisation chemistries are performed for the peptides 
displayed on the phage surface. Such display techniques can then be used to study protein-protein 
interaction and find high affinity binders for a molecular target.  De novo discovery of macrocyclic peptides 
was also explored through in vivo processes in E. coli called split-intein circular ligation of peptides and 
proteins (SICLOPPS) [62]. Biosynthesis of cyclic peptide libraries containing 108 sequences can be 
achieved with this method. In recent years, cell-free techniques such as mRNA display combined with 
flexible in vitro translation (FIT) have been widely applied to screen genetically encoded peptide libraries 
(section 1.4) [63-67]. Researchers have reported that MCPs successfully inhibit protein-protein interactions. 
A study detailed that an MCP discovered using the FIT-RaPID strategy selectively binds and inhibits 
hepatocyte growth factor, a protein involved in cancer progression [68]. The same technique has been 
applied to find inhibitory MCP against Ebola viral protein 24 (VP24) [69]. We hypothesize that, screening 




1.3.2 Affibodies as Ligands 
 
Affibody molecules are engineered small proteins comprised of three alpha helices bundled 
together with molecular weight approximately 6.5 kDa (Fig 5). These small proteins have been largely 
studied as novel and selective binders since their introduction in 1995 by Nord and group [70]. During this 
time, phage display was a well-established method used to screen peptide libraries for target-specific 
binding [48, 70]. The construction of affibodies was carried out to create new ligands for biotechnology 
applications and to serve as “artificial antibodies”. They can fold easily in reducing environments of the 
cell cytoplasm because of smaller structure while resembling antibody-like affinity and binding. The 
scaffold is based on the synthetic Z domain of Staphylococcus protein A (based on B domain of SPA) 
binding to Fc domain of immunoglobulin G. Affibodies have been used as high affinity ligands and have 
many applications like fusion proteins (for e.g., affibody fused with Fc domain of antibody), imaging, and 
detection [71, 72]. A recent study highlights selection of target-based affibody using the phage display 
platform, where affibody ligands were selected for extracellular domain of human epidermal growth factor 
receptor 2 (HER/neu) [73]. The selected affibodies were successfully used in imaging tumors in mice [74, 
75].    
 
Figure 5. Structure of affibody: synthetic Z domain of SPA. It consists of 58 residues that form three α 
helices (H1, H2, and H3) which are stacked together. 
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1.4 In vitro Display Technique for Selecting Peptide/protein Ligands: mRNA Display 
 
Display techniques are effective strategies for screening polypeptide libraries. The principle for all 
display techniques is, that the genotype coding sequence is physically linked with the encoded phenotype, 
the corresponding peptide sequence. This enables for selection of specific binders among trillions of clones. 
The first display technique to screen peptide library for binding was phage display [61]. Since then various 
display techniques have been developed to assist with finding peptide binders. The technology of display 
systems has evolved from cellular approaches such as phage display, yeast display, and bacterial display to 
in vitro display systems [76, 77]. In vitro display technologies have proven advantageous compared to in 
vivo display systems. They have emerged as innovative approaches that allow for screening of large 
diversity of clones in a cell free environment, thus, eliminating biological constraints of a cell [78]. In vitro 
display systems include mRNA display, ribosome display, and DNA based displays [79-82]. The mRNA 
display technique is used to select for peptide/protein binders against a target through evolution of the 
library. An mRNA-peptide fusion is created through the conjugation of puromycin to the mRNA enables 
the linkage of translated peptide/protein to its coding mRNA. Puromycin mimics the 3’ end of an amino-
acyl tRNA which forms a covalent bond with the nascent peptide. To stabilize the mRNA in the mRNA-
peptide complex, a DNA strand is synthesized via reverse transcription forming RNA-DNA hybrid while 
still being attached to the peptide. The target for the display is immobilized on a bead, and the fusion library 
is screened for binders. Each selection round ends in washing of unbound peptides followed by PCR 
amplification of the corresponding cDNA (of the bound peptides), thus, enriching the library with clones 
specific for the target. The major advantage of genotype linkage with the presented peptide scaffold is that 
it is possible to isolate and amplify the positive clones [79, 80] (Fig 6).  
 mRNA display has been adapted for screening of MCP libraries. The display process constitutes 
of in vitro translation system that incorporates non-canonical amino acids required for the cyclisation of the 
peptides. The genetic code is reprogrammed using a tRNA-priming catalyst called flexizyme. It is a 
specialized de novo ribozyme that can charge tRNA with non-canonical amino acids, thus increasing the 
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diversity of peptide library [64]. Flexizyme along with the recombinant translation system can help generate 
macrocyclic peptide libraries which can then be used for discovery of MCP ligands, this is referred to as 
the flexible in vitro translation system (FIT). Random non-standard peptide integrated discovery (RaPID) 
system uses FIT system to discover MCPs for the given target. MCPs discovered through this process have 
high specificity for the target and have been used in wide range of applications. It has been successfully 
used to discover MCPs with inhibitory activity against enzymes [65-68]. 
Figure 6. In vitro Selection of peptide binders using mRNA display technique. The process starts with a 
library of dsDNA, it is then transcribed using in vitro transcription machinery, the mRNA is then ligated 
with puromycin to create puromycin-ligated mRNA library. This is followed by in vitro translation to 
generate a fusion library of mRNA linked with its coded peptide/protein. This fusion library of mRNA-
peptide is reverse transcribed to make RNA-DNA hybrid linked to its corresponding peptide. It is this 
library, that is used for the selection of binders (peptides/proteins that bind to the target). The target is 
immobilized on affinity beads and the library is introduced for binding, followed by several washing step 
to remove unbound proteins. The cDNA of the bound peptides is recovered, PCR amplified and used as 






1.5.1 Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis 
 
The literature study and success of peptide/protein-based therapeutics has inspired us to screen 
artificial genetically encoded libraries of macrocyclic peptide and affibodies for discovery of potential 
inhibitors of MtUGM. The cell wall biosynthetic process can be targeted to tackle Mtb [21]. To do so, we 
have chosen MtUGM as our target. The enzymatic activity catalyzed by MtUGM does not exist in 
mammals, therefore, potential drugs against the enzyme will be specific for the pathogen making it an 
excellent target [83]. With inhibition of MtUGM, UDP-Galf will not be available for priming the galactan 
layer of the Mtb cell wall, subsequently affecting the assembly of the layers above. A dysfunctional cell 
wall affects multiplication, reduces pathogenicity, and makes the bacteria susceptible to other drugs. We 
believe that potential peptide inhibitors can act synergistically with the existing drug regimen. Numerous 
antibiotics targeting the cell wall biosynthesis of bacterial pathogens have been discovered since the first 
use of penicillin in 1930. However, we have witnessed antibiotic resistance towards these drugs, making 
treatment of bacterial diseases difficult. Such is the case with tuberculosis. Though being mostly eradicated 
in the North Americas, the reported TB cases as of 2018 cover 3% of the of the total incidences, including 
cases of resistant TB. Novel therapeutics would thus be beneficial [1, 11]. 
1.5.2 Artificial Genetically Encoded Libraries of Macrocyclic Peptides and Affibodies  
 
Artificial genetically encoded peptide libraries were designed in earlier research by Dr. C. J. 
Hipolito. Construction of an MCP library containing up to 1012 clones was done using the degenerate codon 
NNK to incorporate random amino acids. The peptides to be displayed on mRNA are 15 amino acid in 
length and, in place of N-formylmethionine, have an N-terminal N-(2-chloroacetyl)-L-phenylalanine 
(introduced via a semisynthetic tRNA) to facilitate macrocyclization with the first occurring cysteine in the 
chain. The peptides each have a (Gly-Ser)3 linker at the C-terminal, at which they can be attached to mRNA 
for display. This library of MCPs was used in the FIT-RaPID technique to select binders for MtUGM. The 
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affibody library was generated using the original 58 residue SPA-derived Z domain with 13 degenerate 
positions.  
1.5.3 mRNA Display 
 
The target MtUGM was expressed and purified as fusion protein with MBP bearing an N-terminal 
His6 tag for protein immobilization, the selection was performed against His6-MBP-MtUGM (with His6-
MBP used for negative selection to remove unspecific binders). The mRNA display technique involves in 
vitro transcription that allows the synthesis of a short mRNA sequence to be synthesized from a DNA 
template in a cell-free environment [79]. This is followed by the unique in vitro translation system called 
FIT; a genetic code reprogramming technique based on the combined use of flexizyme-catalyzed 
aminoacylation with a purified recombinant translation system allowing the incorporation of non-canonical 
amino acids. FIT has been applied to the synthesis of proteins containing non-canonical residues and, 
because it allows modification of proteins at an atomic rather than a residue level, is a powerful tool for the 
analysis of protein structure–function relationships [64]. The FIT reaction leads to the synthesis of a library 
of macrocyclic peptides, each of which is covalently linked through the puromycin moiety to its cognate 
mRNA. Each selection round is followed by PCR amplification thus, enriching clones of positive binders. 
The binding ability of individual clones can be determined by using single-clone display (FIT and RaPID 
system in mRNA display of a single sequence rather than a library). Real time polymerase chain reaction 
is a method to efficiently quantify the DNA in real time. This method was employed to quantify the 
recovered cDNA from each selection round from the display. This enables us to quantify the peptides that 
are positive or negative binders. Next-generation sequencing was used to sequence the mRNA library after 
each selection round. MCPs discovered by these means can be chemically synthesized using standard Fmoc 
solid phase synthesis. Selection of affibodies through mRNA display will differ from the FIT-RaPID 
system. In vitro translation of affibody mRNA library does not involve use of unnatural amino acids nor a 
macrocyclization step, but otherwise follows the same steps as MCP selection. The selected affibody can 
then be recombinantly expressed and purified for assays with MtUGM. 
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1.5.4 Development of HPAEC Activity Assay 
 
For testing the potential inhibitory activity of discovered ligands, in our lab we reproduced a 
previously described assay to detect the enzyme activity of MtUGM. We know that MtUGM catalyzes the 
interconversion of isomers UDP-Galp and UDP-Galf, and high-performance anion-exchange 
chromatography (HPAEC) can be used to detect the enzyme activity by distinguishing and quantifying 
these isomers at low levels [83, 84]. 
1.6 Objectives 
 
The broader goal of the project is to develop and find novel therapeutics for treating TB, by 
targeting the process of cell wall biosynthesis in Mtb. This will be achieved by developing peptide/protein 
based potential inhibitors of MtUGM. Towards this goal, we have employed an in vitro selection technology 
that can be adapted to select ligands from two libraries, MCPs and affibodies using mRNA display. Ligands 
discovered through this process will be screened for its inhibitory activity and may be used for studying 
substrate binding interactions which can provide a basis for developing potential drug candidates. 
 
Figure 7. Overview of the project. The aim of this project is to identify the peptide/protein ligands that 
can inhibit MtUGM thereby disrupting the cell wall biosynthesis process in Mtb. Discovered affibodies will 
be used as a tool to study affinity binding interactions.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Recombinant Expression and Purification of Proteins 
 
2.1.1 Recombinant Expression of Proteins 
For all protein expressions, the recombinant plasmid was expressed using BL21 (DE3) E. coli cells 
unless specified. The plasmid was isolated from overnight grown culture of DH10b using ThermoFisher 
GeneJet column Miniprep Kit and expressed in chemically competent BL21 (DE3) E. coli cells. The 
transformants were selected on LB media supplemented with 100 µg/mL ampicillin agar plates. Seed 
culture was prepared, transformants were inoculated into 20 mL LB media supplemented with 100 µg/mL 
ampicillin and grown overnight at 37 ˚C in shaking incubator. Seed culture was prepared, transformants 
were inoculated into 20 mL LB media supplemented with 100 µg/mL ampicillin and grown overnight at 37 
˚C in shaking incubator. 10 mL of seed culture wasp inoculated into an 800 mL LB media supplemented 
with 100 µg/mL ampicillin and grown at 37 ˚C in shaking incubator. This main culture was induced with 
IPTG to a final concentration of 1 mM at log phase (OD600nm = 0.4-0.6). Induced culture was grown 
overnight, at 15˚C in shaking incubator. 
NOTE: The choice of antibiotic will depend on the expression plasmid used.  
2.1.2 Immobilized Metal Affinity Chromatography Purification Using Ni-NTA Column   
For protein purification of his-tagged protein, the overnight grown cultures were harvested by 
centrifuging at 4200g, the pellet was resuspended in 15 ml of binding buffer/resuspension buffer, DNAse 
I, RNAse A and lysozyme were added to a final concentration of 5 µg/mL with the addition of one Roche 
protease inhibitor tablet per 30 ml of resuspended cells. The cells were lysed by sonication and centrifuged 
to remove cell debris. The crude lysate was filtered sterilised using 22 µM filter and applied onto amylose 
resin column preequilibrated with binding buffer. Protein fractions were eluted by AKTA-FPLC with 
elution buffer. The fractions were analysed on SDS-PAGE. The His6-MBP-MtUGM fractions were pooled 
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and concentrated using Vivaspin 6 (30,000 M.W.) concentrator spin columns and stored in storage buffer. 
The final concentration of purified protein was determined by Bradford’s assay or BCA assay. Small 
aliquots of purified protein were flash frozen using liquid nitrogen and stored at -80˚C.  
NOTE: Each protein uses specified buffers suitable for its purification and storage (Table A1). The IPTG 
induction conditions vary for each protein.  
MtUGM 
The pDEST-His6-MBP-MtUGM was obtained from Dr. David Sanders, University of 
Saskatchewan. It encodes wild-type MtUGM fused with maltose-binding protein (MBP) for improved 
solubility and an N-terminal His-Tag used for affinity purification [84]. Protein expression was carried out 
as per section 2.1.1. The protein purification was carried out as per section 2.1.2 with modifications to 
increase yield. After IPTG induction, the cells were incubated in 18°C, harvested after 26 hours, 
resuspended in MtUGM binding buffer. Amylose column was used for affinity purification, fractions were 
eluted with MtUGM elution buffer and stored in MtUGM storage buffer. Final concentration of purified 
TEV protease was determined by Bradford’s assay. This fusion protein was used as a target for selection of 
ligands in mRNA display, where the histidine tag was used to immobilize the protein on magnetic beads.  
TEV Protease 
The pRK793 encodes S219V mutant TEV protease fused with maltose-binding protein (MBP) for 
improved solubility and an N-terminal His-Tag used for affinity purification [85, 86]. The recombinant 
plasmid was designed and deposited on Addgene by Dr. S. Waugh [86]. The plasmid was transformed into 
BL21 (DE3), transformants were selected on LB media supplemented with 100 µg/mL ampicillin and 
chloramphenicol agar plates. Expression was carried out as per section 2.1.1 and cells were cultured in LB 
supplemented with 100 µg/mL ampicillin and chloramphenicol. The harvested cells were resuspended in 
15 ml of TGI buffer. Proteins purification was carried out as per section 2.1.2. with TEV protease elution 
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and storage buffer. Final concentration of purified TEV protease was determined by BCA assay. This TEV 
protease was then used to cleave MBP tag from His6-MtUGM-MBP for enzyme activity assay. 
2.2 Selection of Macrocyclic Peptides Against UGM Using the FIT and RaPID system 
2.2.1   Library Construction  
The NNK15 DNA library of MCPs was designed according to the protocol [67]. The mRNA library 
was transcribed, and it encode 15 NNK (where N = A, U, G, C; K = U/G) positions sequentially to 
incorporate 15 random amino acids. The peptides have an N-terminal N-(2-chloroacetyl)-L-phenylalanine 
(introduced via a semisynthetic tRNA) instead of N-formylmethionine to facilitate macrocyclization with 
the first occurring cysteine in the chain. The NN13 affibody DNA library is based on the template of Z 
domain of SPA with 13 degenerate positions. The peptides each have a (Gly-Ser)3 linker at the end, at which 
they can be attached to mRNA for display. The libraries were amplified using the primers mentioned in 
Table A2. 
2.2.2   Preparation of N-(2-chloroacetyl)-L-phenylalanine-tRNAfMetCAU and Flexizyme eFx 
 
Initiator tRNAfMetCAU and flexizyme dsDNA was amplified using primer extension by PCR. To 
amplify tRNAfMetCAU 0.5µM fMetE-F, 0.5µM fMetE-R2, and 5 ηM fMetE-R1 was used in the final reaction 
mixture for PCR. Amplification of flexizyme dsDNA was done using 0.5µM eFxF66 and 0.5 µM eFx-
AmC-R18 in the final reaction mixture. Phenol-Chloroform-isoamyl alcohol extraction and precipitation 
was performed to extract dsDNA and visualized on 3% agarose gel. In vitro transcription was carried out 
using NEB’s HiScribe T7 Quick Yield RNA synthesis kit, the reaction was incubated overnight in the air 
incubator at 37 ˚C. tRNAfMetCAU and flexizyme eFx was purified by denaturing PAGE with 8% 
polyacrylamide gel. Purified RNA was standardized to 250 µM in the final concentration. Initiator 
tRNAfMetCAU (5.25 nmol) was charged with either N-(2-chloroacetyl)-L-phenylalanine or charged onto 
according to literature protocols. Charged tRNAs for the first rounds of the sub-selections were stored at 
−80 °C as dry pellets. 
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2.2.3   Protein Immobilization on Magnetic Beads 
 
Invitrogen (Grand Island, NY, USA) Dynabeads® His-Tag Isolation & Pulldown magnetic beads 
(40 µg/µl) was saturated with His6-MBP-MtUGM (100 pmol/µl of beads) in MtUGM selection buffer (500 
mM NaCl, 25 mM Tris-Cl pH 7.5, 0.005% TWEEN 20) for positive selection. His6-MBP (50 pmol/µl of 
beads) was also partially saturated on the beads to perform negative selection. The protein-bead mixtures 
were incubated with gentle rotation at room temperature for 20 min. After incubation, the beads were 
washed three times with MtUGM selection buffer to remove unbound proteins. For all selection rounds, 
His-tagged MtUGM (100 pmol) and His-tagged MBP was used to saturate his-tag binding sites on 
Invitrogen Dynabeads® His-Tag Isolation & Pulldown magnetic beads (40 µg) in selection MtUGM  buffer 
for positive and negative selection respectively.  
2.2.4   Preparation of Puromycin-mRNA Conjugated Library 
 
A ligation reaction mixture (1x T4 RNA ligase buffer, 7.5 µM puromycin linker, 10 µM mRNA 
library, 60 Units of T4 ligase, 20 µL) was incubated at room temperature for 3 hours. The reaction was 
quenched with a stop solution (0.6 M NaCl, 10 mM EDTA, pH = 7.5, 20 µL). The solution was extracted 
with 25:24:1 phenol–chloroform–isoamyl alcohol (40 µL) followed by a second extraction with 
chloroform–isoamyl alcohol (40 µL). The mRNA-puromycin conjugates were precipitated with the 
addition of ethanol (80 µL) to the aqueous phase. The resultant precipitate was pelleted by centrifugation 
(15,000g, 15 min), washed with 70% ethanol (20 µL) followed by centrifugation (15,000g, 3 min) and air-
dried. The precipitate was dissolved in water (3 µL). Ligation efficiency was analysed on 8% 
polyacrylamide gel, stained with ethidium bromide, and visualized under UV.  





2.2.5   Flexible In vitro Translation of Puromycin-mRNA Conjugated Library 
 
NEB’s in vitro translation system with customised reagents (NEB Solution A without amino acid 
and tRNA, NEB solution B without RF) called PURExpress® in vitro protein synthesis kit was used. The 
flexible in vitro translation mixture was set up with 19 proteinogenic amino acids, charged N-(2-
chloroacetyl)-L-phenylalanine-tRNAfMetCAU, flexizyme eFx and 10 µM puromycin-mRNA library. It was 
incubated at 37˚C for 30 minutes followed by incubation at 25˚C for 12 minutes to facilitate cyclisation of 
the peptides. To stabilize the mRNA-peptide conjugate, mRNA was reverse transcribed to form cDNA-
mRNA hybrid using Promega reverse transcriptase (-H). The reaction was carried out at 42 ˚C for 1 hour. 
Selection buffer was added to this reverse transcription mix in  1 : 6 ratio and de-salting was done by passing 
the translation reactions through Sephadex G-25 (beads swollen in MtUGM selection buffer for at least 3 
hours)  columns that were pre-washed and equilibrated with MtUGM selection buffer (500 mM NaCl, 25 
mM Tris-Cl pH 7.5, 0.005% TWEEN 20). The library is then used for selection. 
2.2.6   Selection of MtUGM Binding Macrocyclic Peptides 
 
2x blocking solution (0.2% acetylated BSA in selection buffer, 300 µL) was added to desalted 
peptide-mRNA solution. Preclear with magnetic beads partially saturated with His-tagged MBP was used 
to remove peptides that bind to His6-MBP or the beads. The mixture was incubated at 4 ˚C for 10 minutes 
with gentle rotation. This step was repeated three times, where each time the library was added to a new 
microfuge tube. The supernatant was separated from the beads and 0.5 µL of supernatant was used for 
reverse transcription and real-time PCR to measure the concentration of the input peptide-mRNA. From 
this, 300 µL of peptide-mRNA library was added to magnetic beads immobilized with His6-MBP-MtUGM 
and incubated at 4 ˚C for 1 hour with gentle rotation. For negative selection, the remaining peptide-mRNA 
library was added to magnetic beads immobilized with His6-MBP and incubated at 4 ˚C for 1 hour with 
gentle rotation. The supernatant was removed after the incubation period. The beads were washed three 
times with ice cold selection buffer to remove unbound mRNA-peptides. The beads were stripped by adding 
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polymerase free PCR reaction mix (total volume 50 ul) using primers CGS3an13.R39 and T7-CH-F46, 
incubated at 95 ˚C for 5 minutes. For quantification of the peptide-mRNAs recovered by bead binding, 1 
µL of this mixture was removed for use in real-time PCR. The remaining of the solution was thermo cycled 
16 × (95 °C/40 s, 50 °C/40 s, 72 °C/40 s). The PCR product was extracted with one equivalent volume of 
25:24:1 phenol–chloroform–isoamyl alcohol followed by extraction using one equivalent volume of 24:1 
chloroform–isoamyl alcohol. A solution of 3M NaCl was added to the aqueous phase and the DNA product 
was precipitated with the addition of ethanol. Subsequent rounds of selection were performed with 
modification. Total five rounds of selection were done. The DNA molecules obtained after the 5th round of 
both libraries were ligated into the plasmid pGEM-T Easy using TA-cloning. Individual clones were 
selected at random and sequenced by standard sequencing. DNA molecules obtained after each round were 
transcribed and deep sequence analysis was performed using Next-Gen Mi-seq. 
2.2.7   Single Clone Assay  
 
The binding ability of individual clones of peptides was determined by doing the selection process 
using individual peptide-mRNA and the recovered cDNA was quantified using qPCR. 
NOTE: All primers are listed in Table A2. 
2.3 Selection of Affibodies That bind to MtUGM Using mRNA Display 
  
The selection process for affibodies differs from that of MCPs. The FIT system is not applied to 
this process because, the affibodies include all the 20 proteinogenic amino acids. The above-mentioned 
steps in sections 2.3.3 to 2.3.6 were followed for selection of affibodies against MtUGM. 
2.4 Chemical Synthesis of Selected Macrocyclic Peptides 
 
MCPs were synthesised using standard FMOC solid phase synthesis. The N-terminus was protected 
with FMOC (9-fluorenylmethoxycarbonyl) group prior to deprotection with piperidine. This was followed 
by a coupling reaction that added the incoming amino acid and reprotection. This was repeated until the 
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linear peptide chain synthesis was complete.  The peptide was removed from the resin by treatment with 
trifluoroacetic acid (TFA). One-step purification by reverse-phase HPLC was performed to obtain purified 
peptide. The fractions were confirmed for the desired peptide mass using MALDI-TOF mass spectrometry 
and lyophilised. 
2.5 Amplification and Bacterial Cloning of Affibody Genes 
 
The top four affibodies as per mRNA display final round were selected for recombinant expression. 
For cloning into pET21a-GFP the genes were designed to have BglII at 5’ end followed by the T7 promoter, 
affibody gene, (Gly-Ser)3 linker, TEV protease recognition site and 3’ NdeI restriction site. The gene 
synthesized by Twist Bioscience. Affibody sequences were PCR amplified using primers AFR6-F and 
AFR6-R, purified by using Bio Basic PCR purification kit. Amplified affibodies were cloned into pET21-
GFP by restriction digestion of said restriction sites. The recombinant plasmid encoded His-tagged affibody 
tagged with GFP, with a TEV protease recognition site in between. DH10b cells were transformed with the 
recombinant plasmid and plated on LB-agar supplemented with 100 µg/mL of ampicillin. Six colonies were 
selected arbitrarily from the four plates and inoculated in 5 ml culture, grown overnight at 37 ˚C in shaking 
incubator. To ensure proper cloning plasmid isolated from these overnight cultures were screened by colony 
PCR (primers: AFR6-insert-F and AFR6-insert-R). Additionally, standard sequencing was performed to 
confirm successful insertion of affibody genes, sequences were aligned in SnapGene. 
NOTE: All primers are listed in Table A2. 
2.6 Recombinant Expression and Purification of Affibodies (AFR6-1,4) 
 
The recombined plasmids (section 2.6) isolated from overnight cultures of DH10b cells. Affibodies 
were expressed and purified as per section 2.1.1 and 2.1.2. Affibody elution buffer and storage buffer were 
used for the process. (Table A1). Concentration of purified affibody-GFP fusion protein was determined 
by Bradford’s assay.  
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2.7 Enzymatic Assay using High-Performance Anion-Exchange Chromatography 
 
  Digested His6-MBP-MtUGM was used for enzymatic assay. The dual tag was removed via TEV 
protease cleavage. The digestion mixture was setup with 1:10 ratio His-tagged TEV protease to fusion 
protein; incubated overnight at 4˚C. The His-tagged TEV protease and His6-MBP were removed using 
IMAC by loading the digested fusion protein onto Ni-NTA column. Flow-through fractions containing 
untagged MtUGM were collected and analysed on SDS-PAGE. Final concentration was determined by 
Bradford’s assay. Enzymatic activity of purified MtUGM was determined using high proficiency anion-
exchange chromatography by monitoring the conversion of UDP-Galp to UDP-Galf at 262nm. The final 
reaction mixtures included a fixed amount of enzyme MtUGM (200 nM) and varying amounts of substrate 
UDP-Galp (25-200µM), in 50 mM sodium phosphate buffer (pH 7) with 20 mM freshly prepared sodium 
dithionite to a final volume of 100 µl.  The control reaction contained only UDP-Galp. The reaction was 
carried out for 2 min at 37˚C and quenched with equal volume of n-butanol. The aqueous layer, containing 
UDP-Galp and UDP-Galf, was obtained by centrifugation and 10 µl was injected into CarboPac PA1 HPLC 
column. The sugars were eluted isocratically with 200 mM ammonium acetate (pH 7) buffer with a flow 
rate of 0.5mL/min; run time was set at 20 min. The area under the curve and peaks were integrated using 
Agilent Chemstation software. The % conversion of UDP-Galp to UDP-Galf was calculated using the 
following formula: 
 
% 𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 =  
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑈𝐷𝑃-𝐺𝑎𝑙𝑓 𝑝𝑒𝑎𝑘
𝐴𝑟𝑒𝑎 𝑜𝑓 𝑈𝐷𝑃-𝐺𝑎𝑙𝑝 𝑝𝑒𝑎𝑘 + 𝐴𝑟𝑒𝑎 𝑜𝑓 𝑈𝐷𝑃-𝐺𝑎𝑙𝑓 𝑝𝑒𝑎𝑘 






CHAPTER 3: RESULTS 
 
 
3.1 Selection of MtUGM binding MCPs and Affibodies 
 
MtUGM plays a key role in the assembly of the cell wall in Mtb, it is responsible for the interconversion 
of sugar isomers UDP-Galp and UDP-Galf. To find binders specific for MtUGM we recombinantly 
expressed and purified his-tagged, MBP-fused MtUGM. The his-tag is important for attaching the enzyme 
on magnetic beads for carrying on the selection process. We selected two ligand libraries for mRNA display 
the affibodies and MCPs. The selection process is same except the display of affibodies does not require 
FIT. 
3.1.1 Construction of plasmids encoding mutants of MtUGM 
 
The enzyme has been co crystallised with its substrate and inhibitors giving insights about the binding 
pockets. Dr. David Sanders’ lab has successfully expressed MtUGM and elucidated the crystal structure 
[84]. Originally, pDEST-His6-MBP-MtUGM was constructed via gateway cloning (Fig 8a). Based on the 
crystal structure we decided to create point mutants of the wild type enzyme. These mutations are made in 
the active site of MtUGM. These residues are important for making interactions with the substrate at the 
active site and change in which will affect the binding efficiency [87]. The active site mutants can be used 
in the negative selection (section 3.1.8) to remove enzyme surface binders. Two mutants were constructed, 
3FMtUGM (Fig 8b) with three mutations in the active site and 7xMtUGM (Fig 8c) with seven mutations 





Figure 8. Plasmid constructs for expressing the target protein MtUGM as a his-tagged, MBP fusion(a) 
pDEST-His6-MBP-MtUGM and the construction mutants (b) 3FMtUGM and (c) 7xMtUGM. 
 
 
3.1.2 His-tagged, MBP-fused MtUGM and MtUGM 
 
The recombinant plasmid encoding MtUGM as a His-tagged MBP fusion protein was obtained from 
Dr. David Sanders. pDEST-His6-MBP-MtUGM (Fig 9a) is encoded with a TEV cleavage site between the 
dual tag and MtUGM sequence. The recombinant His-MBP-MtUGM fusion protein was purified by affinity 
chromatography. The MBP tag of the fusion protein binds to the amylose resin and was eluted with elution 
buffer containing maltose. SDS-PAGE analysis of purified protein fractions is shown in Fig 9.  The His6-
MBP-MtUGM fusion protein was purified and was observed at ~87 kDa (Fig 9a). The second band at ~43 
kDa presumably corresponds to His-MBP. It is possible that the dual tag had cleaved prior to or during the 
purification process or was expressed as a prematurely truncated protein. We successfully obtained, a final 
concentration of 0.5 mg/mL, determined by BCA assay, yielding a total of 1.5mg of fusion protein from 
800ml of culture. However, we optimised the protocol to obtain the purest fraction of His6-MBP-MtUGM 
by pooling the single-band fraction, the concentration of which was 0.3 mg/mL in a  total volume of 2ml. 
Expression and purification of the mutants followed the same procedure as the wild type. The SDS-PAGE 
gel for mutants 3FMtUGM (Fig 9b) show that expression and purification was successful and ~1.5 mg of 
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protein was obtained from 800ml culture. The expression of 7xMtUGM (Fig 9c) was not successful, it is 
possible that the protein folding efficiency was affected due to the mutations. 
 
 
Figure 9. SDS-PAGE analysis for recombinant expression of MtUGM (a) His6-MBP-MtUGM (b) His6-MBP-
3FMtUGM and (c) His6-MBP-MtUGM. 
 
The recombinant plasmid pRK793 encodes a MBP-His6-TEV for improved expression of soluble 
protein, however the fusion of the TEV protease is self-cleaving at a sequence following the MBP portion, 
leaving an active His6-TEV that was purified via IMAC affinity chromatography (Fig A4 a). Elution 
fractions were analysed on SDS-PAGE for size and purity.  MBP-His6-TEV fusion protein has theoretical 
molecular weight of ~70 kDa whereas cleaved His6-TEV protease has a molecular weight ~30 kDa. Fig A4 
b shows the successful purification of His6-TEV protease. Despite the presence of uncleaved fusion protein, 
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catalytically active TEV protease was obtained.  A final concentration of 1.77 mg/mL was determined by 
BCA assay and a total of 5.30 mg TEV protease was obtained from a 2 L culture.  
The protocol followed to obtain purified MtUGM from His6-MBP-MtUGM by TEV protease, has been 
previously established. To obtain pure MtUGM, the His6-MBP-MtUGM protein was digested with TEV 
protease, which cleaves a recognition sequence following the MBP portion. After digestion, the cleaved 
fusion protein, resulted in a His6-MBP (~42.5 kDa) fraction and a purified MtUGM (~45 kDa). This mixture 
was filter sterilised, applied to N-NTA column and IMAC was performed. The untagged MtUGM was 
eluted in the flow-though fractions, and His6-MBP along with TEV protease were eluted with buffer (20 
mM Tris, 250 mM NaCl, 220 mM Imidazole, pH 7.5).  However, we observed another band at ~55 kDa, 
the reason for which is unknown (Fig 10). Nonetheless, A final concentration of purified MtUGM after 
TEV digest was determined to be 0.278 mg/ml by BCA assay.  
 
 
Figure 10. SDS-PAGE analysis of MtUGM digested with TEV protease. Lanes 1, 2 and 3: fractions 
containing His6-MBP and TEV protease eluted with imidazole. Lanes 4, 5 and 6:  flow-through fractions 




3.1.3 Immobilisation of His6-MBP-MtUGM and His6-MBP on Dynabeads. 
 
To carry out the selection process, we immobilized the His6-MBP-MtUGM selection target and His-
MBP counter-selection target. The latter was used for negative selection (preclearing) to remove non-
specific peptides since our goal was to identify binders to MtUGM. His-tag isolation magnetic beads were 
used for the immobilization. We determined the concentration of proteins that was ideal to saturate the bead 
surface by observing the beads coated with the protein and the supernatant on SDS-PAGE gels. We tested 
different concentrations and the results suggest that for our His6-MBP counter-selection target (~43kDa), 
50 pmol/l of protein partially coat the beads (Fig 11a). We found that 100 pmol/l of beads is the 
concentration at which the beads are completely saturated with our His6-MtUGM-MBP selection target 
(~87kDa) (Fig 11b). The beads saturated with the proteins were used for the selection process. 
 
3.1.4 Preparation of eFX and tRNAfMetCAU for Flexible in vitro Translation of Macrocyclic 
Peptides  
 
Catalytic RNA ribozymes known as flexizymes were previously developed via in vitro evolution as a 
tool to expand the genetic code for cell-free protein translation, they can charge any E. Coli of tRNA with 
a variety of non canonical amino acids. Flexizyme eFx is capable of charging tRNA with a chloroacetyl 
modified aromatic amino acid. We synthesised dsDNA of flexizyme and tRNAfMetCAU by primer extension 
polymerase chain reaction. The dsDNA of tRNA and eFx was visualised in 3% agarose gel at 99bp and 
66bp, respectively (Fig 12a). The dsDNA was reverse transcribed, and RNA was purified denaturing PAGE 
visualised under UV (Fig 12b).   N-(2-chloroacetyl)-L-phenylalanine-tRNAfMetCAU was prepared by 
incubating eFx and initiator tRNAfMetCAU which served as methionine during flexible in vitro translation. 































Figure 11. SDS-PAGE analysis of protein immobilisation on his-tag isolation beads (a) 25, 50 and 75 pmol 
of His6-MBP was saturated on 1 ul of beads, and 50 pmol of His6-MBP showed complete saturation, 25, 50 
and 100 pmol was saturated on 1 ul of beads, the gel was inconclusive thereby, was repeated again (b) 
25, 50, 100, 150 and 200 pmol of His6-MBP-MtUGM was saturated on 1ul of beads and 100 pmol of His6-






Figure 12. Preparation of tRNAfMetCAU and Flexizyme (eFx) (a) PCR amplification of tRNA and flexizyme 
dsDNA (b) RNA purification using denaturing PAGE. 
 
 
3.1.5 Preparation of Puromycin-Ligated mRNA Library 
 
Puromycin plays a critical role in mRNA display, it attaches the translated peptide to its encoding 
mRNA. Ligation of puromycin was achieved by incubating the mRNA libraries coding the affibody and 
macrocyclic peptides with puromycin. The ligated library was purified and analysed on denaturing PAGE. 
The puromycin ligated library can be observed as a higher band on the gel compared to the unligated library 






Figure 13. Denaturing PAGE analysis of puromycin ligated mRNA libraries (1) Macrocyclic peptide mRNA 
library (2) Macrocyclic peptide mRNA-Puromycin (3) Affibody mRNA library (4) Affibody mRNA-Puromycin 
(5) Monobody mRNA library and (6) Monobody-Puromycin. 
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3.1.6 Selection of MtUGM Binding Macrocyclic Peptides 
 
To identify MCPs for MtUGM we employed the RaPID system. The mRNA template library was 
designed to have 5′-AUG-(NNK)n-UGC-3′, where AUG and UGC assign chloroacetyl amino acid 
(ClAcLPhe) and Cys, respectively, and where, NNK15 (N represents any of four bases and K represents U 
or G) assign all possible 20 amino acids at 15 degenerate positions in the coded peptide. The library is 
ligated with puromycin prior to peptide translation, which allows the peptide synthesised to remain attached 
to its coding mRNA. The in vitro translation using N-(2-chloroacetyl)-L-phenylalanine enables spontaneous 
cyclisation with the first occurring cysteine in the peptide chain by forming thioether bond creating a library 
of 1012 macrocyclic peptides. This is followed by reverse transcription to stabilize the mRNA by creating 
mRNA-DNA hybrid which is linked with the corresponding peptide. Prior to the selection process, the 
library was subjected to negative selection (preclearing) using His6-MBP (our counter-selection target) 
immobilised to beads. The library was then subjected to RaPID selection using His6-MBP-MtUGM that 
was immobilized on Ni2+-NTA magnetic beads via the interaction with the hexa-histidine tag. We also 
incubated the precleared library with His6-MBP as a negative control. The binding steps were carried out 
at 4°C. After the first round of selection, the cDNA was recovered and qPCR was performed to analyse the 
recovered amount of DNA, which was then PCR amplified for the next round. This was followed by in 
vitro transcription of the recovered library and puromycin ligation. Subsequently, in vitro translation and 
reverse transcription were performed to generate an enriched mRNA-DNA-peptide fusion library. This was 
repeated and the selection process continued until we observed enrichment of positive binders.  
Figure 14a depicts the progress of selection process. At the fifth round, we observed an appreciable 
enrichment of MCPs binding to the target in the pools monitored by the recovery amount of selected cDNA 
by RTPCR, while the binding to His6-MBP (immobilized to magnetic beads) was significantly low. The 
recovered library was 1.5% of the input library. We plotted the positive to negative ratio, where positive 
refers to the MCPs binding to His6-MBP-MtUGM and negative refers to His6-MBP binders (Fig 14b). This 






Figure 14. Selection of MtUGM binding macrocyclic peptides (a) Progression of selection through 
individual rounds, percentages of peptides bound were determined by dividing the amount of recovered 
cDNA by the amount of input macrocyclic peptide-mRNA conjugate. (b) The positive to negative ratio 
determined by dividing the percentage recovery of macrocyclic peptide-mRNA conjugate binding to His6-




























































3.1.7 Single Clone Assay 
 
To assess the selection process at the end of round 5 we randomly isolated 20 clones by TA cloning 
and performed standard sequencing.  The sequences reveal the appearance of HHR motif and macrocycles 
with one representing a mini cycle at the C terminal (Table 1).  
Table 1. Macrocyclic peptides isolated for single clone assay 
Clone  Sequence 
UGM-R5-4  ClAcLF RHSCHTQHHRLTHHQCGSGSGS 
UGM-R5-6  ClAcLF HKHTAHHRTHTHRRCGSGSGS 
UGM-R5-18  ClAcLF HSTHHWHQHHRQCGSGSGS 
UGM-R5-19  ClAcLF KTPWRHHHNTLTHRNCGSGSGS 
UGM-R5-20  ClAcLF KQKRHHYHRHKHQLNCGSGSGS 
 
 
The clones were then tested for their binding and specificity against MtUGM. UGM-R5-19 was observed 
with highest recovery at 5.8% of the input amount, and UGM-R5-20 reports the lowest at  0.1% of the input 
amount (Fig 15a) , however, the positive to negative ratio is significantly higher indicating that the binders 








Figure 15. Single clone assay for selected MCPs (a) %cDNA recovery of Macrocyclic peptides binding to 
His6-MBP-MtUGM and His6-MBP (b) The positive to negative ratio for individual clones determined by 
dividing the percentage recovery of macrocyclic peptide-mRNA conjugate binding to His6-MBP-MtUGM 





























































3.1.8 Selection of MtUGM Binding Affibodies 
 
Affibodies are relatively larger (6.5 kDa) than MCPs (2 kDa) in size. mRNA display of affibodies is a 
novel approach to find ligands for the target enzyme. The affibody library template consists of NNK 13 
codons that code for 13 random amino acids shown below (Fig 16). The codons that encode a random 
amino acid are placed on the helix front of the two out of three helices, which make interactions with a 
target protein. Affibodies are high affinity ligands, thus, studying the evolution of these degenerate positions 
will provide information on ligand binding and highlight the essential amino acid motifs. 
 
 
Figure 16. Affibody library template. The X denotes the amino acids encoded by NNK degenerate 
positions. The residues in red represents the random amino acids, essentially placed on the helix front. 
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In vitro translation of the Affibody mRNA library conjugated with puromycin incorporates all 20 
natural amino acids. The translated affibody is thus attached to its coding mRNA creating an affibody-
mRNA conjugate. This library was precleared by applying it to beads immobilised with His6-MBP to 
remove binders to beads and His6-MBP prior to the selection process. The precleared library was then 
applied for selection using His6-MBP-MtUGM immobilised on beads. We also incubated the precleared 
library with His6-MBP as a negative control. The binding steps were carried out as described in section 
3.1.6. Fig 17a show that at round 5 we observe the steep increase in % cDNA recovered as positive binders 
(i.e. affibodies that bind to His6-MBP-MtUGM) at 0.1 % and the negative binders at 0.005%. We plotted 
the positive to negative ratio, where positive refers to the MCPs binding to His6-MBP-MtUGM and negative 
refers to His6-MBP binders (Fig 17b). This ratio however does not indicate affinity of binding or the 
frequency of selected clones.  
3.1.9 Next-Gen MiSeq Analysis of Sequence Enrichment During Selection Rounds.  
 
mRNA libraries from each round were sequenced using Next-gen MiSeq to analyze the sequence 
enrichment during the selection progress. For the MCP library we selected the top 20 sequences (Table 2) 
from round 5 and plotted the gene frequencies from each round to generate an evolution graph. We can see 
the increase in the gene frequency of the selected clones in round 3, with highest frequency observed at 
round 5 (Fig 18a). Similarly, we plotted the evolution graph for affibodies, which shows that the sequences 
enriched in the last round of selection begin to appear at round 4 and we observe a significant enrichment 









Figure 17. Selection of MtUGM binding affibodies (a) Progression of selection through individual rounds, 
percentages of peptides bound were determined by dividing the amount of recovered cDNA by the 
amount of input affibody-mRNA conjugate. (b) The positive to negative ratio determined by dividing the 
percentage recovery of affibody-mRNA conjugate binding to His6-MBP-MtUGM by recovery of affibody-

































































Figure 18. Next-gen analysis: evolution graph of peptide/protein sequences (a) Enrichment plot of the 

























































































Table 2. Macrocyclic peptide sequences from Round 5 and their frequency of occurrence. 
Clone Sequence R1 R2 R3 R4 R5 
MCPR5-1 ClAcLF RHSCHTQHHRLTHHQCGSGSGS* 0 0 0.08 0.78 3.10 
MCPR5-2 ClAcLF KKHHRPIHRRHHTHCGSGSGS* 0.01 0.01 0.004 0.60 3.05 
MCPR5-3 ClAcLF HTQCSSHSRSHHHHCGSGSGS* 0.01 0 0.10 0.58 2.88 
MCPR5-4 ClAcLF TWNPHRHKCHTHTHHCGSGSGS* 0 0 0.09 0.48 2.56 
MCPR5-5 ClAcLF HHLHRRHHAHTHCGSGSGS* 0.01 0 0.10 0.61 1.86 
MCPR5-6 ClAcLF HHRHKIPAHTRHHRSCGSGSGS* 0.01 0 0.04 0.35 1.80 
MCPR5-7 ClAcLF HLKHHRAPHHRTHNCGSGSGS* 0 0 0.02 0.32 1.42 
MCPR5-8 ClAcLF VTHHHPKHRAHLHMHCGSGSGS* 0 0 0.05 0.002 1.19 
MCPR5-9 ClAcLF RHKHHRPRHHYPSHCGSGSGS* 0 0 0.02 0.31 0.95 
MCPR5-10 ClAcLF RHHRQDHHHTQHGSGSGS* 0 0 0.02 0.21 0.90 
MCPR5-11 ClAcLF HAHHDTHKTRHRHHCGSGSGS* 0 0 0.06 0.002 0.85 
MCPR5-12 ClAcLF HQKYHHSHRHDPAHKCGSGSGS* 0 0.02 0.004 0.002 0.79 
MCPR5-13 ClAcLF KKHHSHHPYHQTHKHCGSGSGS* 0 0 0.02 0.15 0.72 
MCPR5-14 ClAcLF YRSHHHHKHHDTRIHCGSGSGS* 0 0 0.03 0.17 0.72 
MCPR5-15 ClAcLF HKHTAHHRTHTHRRCGSGSGS* 0 0 0.02 0.28 0.71 
MCPR5-16 ClAcLF KRNHRIHHRYPHLHHCGSGSGS* 0 0.01 0.02 0.22 0.67 
MCPR5-17 ClAcLF MHRHHRHKHLNHTTCGSGSGS* 0 0.01 0.04 0.28 0.64 
MCPR5-18 ClAcLF KNLHHHRHTTHHHCGSGSGS* 0 0 0.08 0.002 0.60 
MCPR5-19 ClAcLF SNHHPRHHHVPHRLHCGSGSGS* 0 0.01 0.03 0.17 0.59 









Table 3. Affibody sequences from Round 6 and their frequency of occurrence in round 4,5 and 6. 
Clone Sequence R4 R5 R6 
AFR6-1 MVDNKFNKEVLLAVIEIRVLPNLNLVQFSAFIWSLDDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.01 0.04 0.11 
AFR6-2 MVDNKFNKERCMALFEIVFLPNLNLIQFYAFIVSLTDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.01 0.02 0.1 
AFR6-3 MVDNKFNKECFLAILEIAWLPNLNCLQFFAFILSLGDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.03 0.02 0.09 
AFR6-4 MVDNKFNKELLLALVEIVFLPNLNLVQGFAFILSLVDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.01 0.01 0.09 
AFR6-5 MVDNKFNKEHWLAFMEIVVLPNLNLVQVFAFIWSLSDDPSQSANLLAEAKKLNDAQPKGSGSGS* 0.01 0 0.08 
AFR6-6 MVDNKFNKEVTLAFWEIRWLPNLNVVQLYAFILSLGDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.03 0.04 0.08 
AFR6-7 MVDNKFNKEMSLAFVEITWLPNLNGWQLCAFIVSLRDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.05 0.02 0.08 
AFR6-8 MVDNKFNKEWLVAYIEIVWLPNLNFMQSYAFILSLVDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.04 0 0.08 
AFR6-9 MVDNKFNKEWVVAIVEIAYLPNLNKMQIFAFIISLSDDPSQSANLLAEAKKLNDAQAPKGSGSGS 0 0 0.08 
AFR6-10 MVDNKFNKEACFALWEIWFLPNLNIVQGFAFIWSLRDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.01 0 0.08 
AFR6-11 MVDNKFNKELLVATLEIVFLPNLNWVQLVAFILSLSDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.04 0.01 0.08 
AFR6-12 MVDNKFNKEWLLAYYEILLLPNLNGVQFYAFIVSLSDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0 0.02 0.06 
AFR6-13 MVDNKFNKECWLALLEIWVLPNLNVAQFSAFIWSLGDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0 0 0.06 
AFR6-14 MVDNKFNKEWTLALIEITWLPNLNWFQWTAFILSLFDGPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.13 0.02 0.06 
AFR6-15 MVDNKFNKEELMAVIEIWFLPNLNSMQLFAFILSLMDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0 0 0.06 
AFR6-16 MVDNKFNKELVIAYTEIVVLPNLNMIQVFAFIMSLSDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.05 0.01 0.06 
AFR6-17 MVDNKFNKERFLALIEIVKLPNLNLFQGFAFIVSLRDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0 0 0.06 
AFR6-18 MVDNKFNKEFWVAHWEIWCLPNLNCVQGFAFIYSLVDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0 0 0.06 
AFR6-19 MVDNKFNKEVFFAVFEIKWLPNLNYGQLQAFIVSLSDDPSQSANLLAEAKKLNDAQAPKGSGSGS* 0.01 0 0.06 




3.2 Recombinant Expression and Purification of Affibody 
 
The top 4 affibody sequences revealed after round 6 of mRNA display were used for recombinant 
expression of affibody genes (section 3.1.11, Table 3). The plasmid pET21a-GFP was used to express 
affibody conjugated with green fluorescent protein. The construct consists of N-terminal hexa-His tag for 
affinity purification and TEV protease recognition site between the affibody sequence and GFP (Fig 19). 
The affibody genes were cloned into pET21a-GFP. Cloning was performed via restriction digestion and 
ligation and transformation of DH10b cells. Expression was carried out by transforming BL21(DE3) cells 
induced with IPTG. Purification was performed by IMAC using an Ni-NTA column. The fractions were 
collected by Akta-FPLC and analysed on SDS-PAGE (Fig 20). His-tagged AFR6-1-GFP has a theoretical 
molecular size of ~35.7 kDa. The final concentration of 0.48 mg/ml per 1 L of culture was determined by 
the BCA assay, this fraction also contained non-specific proteins eluted along with AFR6-GFP which could 
not be separated. His-AFR6-2-GFP protein has a theoretical molecular weight of 36 kDa. Similarly, the 
eluted fractions seem to contain AFR6-2-GFP. The concentration was determined to be 0.17 mg/mL. AFR6-
3-GFP has a theoretical molecular size of ~36 kDa. As seen on figure 9, AFR6-3-GFP corresponding bands 
were present.    
 
 





Figure 20. SDS-PAGE analysis of purified AFR6-1-GFP, AFR6-2-GFP and AFR6-3. (a) Lane 1: lysate, lane 2: 
the flow-through fractions, lane 3: wash fraction, and lanes 4 to 11: elution fraction containing AFR6-1-
GFP. (b) Lane 1- flow-through fractions, lane 2-wash fraction, and lanes 3 to 8: elution fractions containing 
AFR6-2- GFP. (c) Lane 1: flow-through fractions, lane 2-wash fraction, and lanes 3- elution fraction 







3.3 HPAEC Activity Assay of MtUGM 
 
To detect MtUGM enzyme activity we used previously described high-performance anion 
exchange chromatography with some modifications [83]. CarboPac PA1 column (Dionex Inc) 
preequilibrated with 200mM ammonium acetate was used to detect UDP-Galf and UDP-Galp peaks at 262 
nm. The enzyme activity was confirmed by the detection of the product UDP-Galf at 262 nm. The reaction 
was set up with the varying concentrations of the substrate UDP-Galp concentrations (25-125µM), a fixed 
amount of MtUGM (200nM) as per section 2.8.  The negative control was set up with no enzyme. Figure 
21 shows the peaks for UDP-Galp and UDP-Galf separated by baseline resolution were detected at around 
6.2 min and 8.5 min, respectively. At equilibrium, the pyranose form is favoured UDP-Galp : UDP-Galf 
being 97:7 as previously reported [24]. Based on our assay, the % conversion of UDP-Galp to UDP-Galf 
was 6.32%, which is close to the reported data. Reported studies have successfully used this assay technique 
for testing the inhibitors of MtUGM (and other bacterial UGMs) by calculating the % conversion of the 
substrate to the product. However, these research groups have used UDP-Galf as the substrate, since, the 
equilibrium favors the conversion of UDP-Galf to UDP-Galp. Studies show that when UDP-Galp is used 
as a substrate, most of the product (UDP-Galf) is converted to UDP-Galp, because the equilibrium favours 
the formation of UDP-Galp reaction. Thus, characterizing the MCPs and affibodies for inhibition using 
UDP-Galf as substrate may be considered. Nonetheless, our results show the detection of UDP-Galf peak, 












Figure 21. HPAEC activity assay of MtUGM. The peaks for UDP-Galp and UDP-Galf is detected at around 
6.2 minutes and 8.5 minutes, respectively. (a) Negative control- reaction was carried out with no MtUGM. 




CHAPTER 4: DISCUSSIONS 
 
 
The application of mRNA display platform as a tool to identify target-specific peptide/protein 
ligands from highly diverse libraries has been gaining popularity. Over the past two decades, a growing 
interest in rational design and screening of synthetic libraries of engineered proteins for therapeutic 
applications has been reported. The focus has been towards the generation of vast peptide libraries and 
developing high throughput screens to facilitate discovery of novel hits for specific targets. Apart from the 
broader goal of therapeutic application, peptide/protein-based ligands have been used to elucidate the 
binding interactions with the target protein; information that can play an essential role in developing novel 
drugs. With increasing incidences of antibiotic resistance, we notice a paradigm shift in the techniques 
involved in discovering novel antibiotic drugs. In our project, we have used an established display platform 
that relies on in vitro transcription-translation mechanisms to discover macrocyclic peptides and affibodies 
for our selected molecular target MtUGM. 
 
4.1 mRNA Display: Discovery of MtUGM Binding MCPs and Affibodies  
Early on we hypothesized that selection process could be targeted towards the selection of 
macrocyclic peptide specific for the active site of MtUGM by using an active-site triple-mutant negative 
selection target to exclude binders that interact outside of the active-site. The published crystal structure of 
MtUGM highlights the role of active site residues in ligand binding. Thus, by having an active site mutant 
as a negative screen to fish out all surface binders seemed like a promising strategy.  However, further 
consideration led us to believe that it will be difficult to achieve this goal as it would be a bottle neck for 
finding binders and thus we would lose the variety in the initial rounds if we include such a stringent 
negative selection, which is undesirable. Negative selection using active site mutants might also result in 
loss of potential allosteric inhibitors. Thus, for our study we concentrated on finding ligand binders and 
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later we would like to proceed with crystallography to identify the nature of binding, based on which we 
could try a directed selection process through which we can select for binders specific to the active site. 
The purification of 7x-MtUGM mutant was not successful, we suspect this is due to misfolding of protein 
due to seven mutations. The 3F-MtUGM active-site mutant created in this project may be useful in future 
studies as per the above stated reasons.  
For the selection process, we obtained the target MtUGM through recombinant expression and 
purification (Fig 9). The purification of the target and the dual tag was carried out using affinity 
chromatography. It was a challenge to acquire a pure fraction of fusion protein His6-MBP-MtUGM, as it 
was suspected that the fraction would contain traces of His6-MBP resulting from the premature termination 
of the His6-MBP-MtUGM fusion. This could pose a problem during the selection process. This was 
overcome by collecting the purest fractions (i.e. the first fraction collected, Fig 9) however, the yield was 
low. To overcome this, His6-MBP-MtUGM was expressed in Rosetta (DE3) following previously 
mentioned protocol in section 2.1, the purest fraction were collected from several batches and pooled 
together to obtain a final concentration of 0.3ml/mL in a total volume of 2 mL. Additionally, this was 
addressed by having His6-MBP-bound beads for the pre-clearing of the peptide-mRNA library and as a 
negative control. 
The selection of MCPs was done via the RaPID system. During the process, we faced difficulty in 
achieving a good efficiency of puromycin ligation between the selection rounds. Thus, we suspect that this 
may have resulted in a loss of diversity at this step. mRNA Display of affibodies was continued until round 
6, appreciable enrichment was observed between the round 5 and 6. However, recovery of cDNA was at 
0.1% which is low compared to MCPs. The PCR amplification of the affibody library also posed a challenge 
due to the amplification of non-target DNA sequence, thereby affecting the library diversity and template. 
We applied gel purification of mRNA to retrieve the correct size of the library however, we lost some 
library during the purification process.  
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4.2 Next-gen MiSeq Analysis  
  
Through next-generation sequencing analysis, the evolution graph plotted for all the occurring 
MCP sequences shows a trend in the enrichment of clones as the selection progressed (Fig A1). However, 
the evolution graph plotted for affibodies did not show a definite trend. Thus, we plotted the change in gene 
pools from individual rounds. The evolution graph for the top 20 sequences of affibodies in round 6 reveals 
that these sequences coding the corresponding affibodies were seen after the third round of selection. A 
general pattern of a dip in gene frequency before its increase was observed for most sequences except AR6-
1, 2, 3, 6, 12, and 20 (Fig 18b). It was also interesting to note that the evolution graph plotted for the top 
sequences appearing in round 5 of affibody selection shows that AFR5-10, (which is the same sequence as 
AFR6-6) dominates the selection (Fig A2). Further bioinformatics analysis is required for elucidating the 
factors that influence a selection process; the knowledge of which can also be utilized as a basis for 
designing new ligand libraries. For example, investigating the emergence of motifs in the peptides/proteins 
can shed light on binding interactions. Ligands discovered through this process were synthesized. We aim 
to characterize them for specific functions.  
4.3 Synthesis of Desired Ligands Identified Via In vitro Selection  
 
Due to its smaller size and length (15 amino acids) in MCPs can be chemically synthesized.  UGM-
R5-19, UGM R5-20 (and fluorescently labeled MCPs) were chemically synthesised by Dr. Christopher 
Hipolito. Chemical synthesis of affibodies is not efficient, thus we recombinantly expressed and purified 
these affibodies. However, additional optimization of the protocol is required. The procedures were adapted 
from literature for affibody expression which stated use of denaturing conditions for purification followed 
by refolding; however, these were not tagged with GFP. We speculated that using denaturing conditions 
for GFP would result in an unfolded protein that would not be easy to refold, so we excluded denaturing 
conditions from our procedure. We were able to express low concentrations of affibodies fused to GFP, this 
could be due to insoluble protein. It was observed that the affibody tagged with GFP was present largely in 
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the insoluble fraction as we found GFP in the cell debris (visualised by fluorescence excitation under UV 
light, wavelength 350-400nm) after lysis and protein extraction, suggesting we lost recombinant protein 
with the cell debris. We can try optimising the buffer conditions to increase the solubility, use an MBP tag 
(for solubility), or increase sonication time. Though we were able to successfully express the affibodies, 
we found it challenging to obtain pure fractions during the elution process, and thus contaminating proteins 
eluted along with affibodies contributed to the final protein concentration. Improvements like the use of 
different affinity columns, such as a TALON resin, or use of size-exclusion chromatography to isolate 
desired proteins by its molecular size may be attempted to obtain better results.  
 4.4 Establishing HPAEC Assay for Testing Potential Inhibitors 
 
Our HPAEC assay is based on previous literature, where it has been used to test enzyme activity 
and screen potential inhibitors. However, the method for running the HPLC varies, thus, the assay we used 
has been developed after considering some modifications. HPLC data is dependent on run time, flow rate, 
injection volume and the eluent concentrations. Previous papers have reported varying flowrate and run 
time. After the observation that the last peak is detected before 12 minutes, run time was set at 20 minutes. 
Even though the peaks for UDP-Galf and UDP-Galp appear much earlier than reported data, we confirmed 
that the identified peaks are correct. The peaks were compared against standards of UDP and UDP-Galp, 
and against two blanks (enzyme in reaction buffer and reaction buffer without substrate or enzyme). 
However, we were not able to confirm the peak for UDP-Galf against an authentic standard. To check if 
reaction incubation time (enzyme along with the substrate) affects the amounts of the product UDP-Galf, 
we let the reaction proceed for 2 minutes and 10 minutes, no significant change was observed. The end goal 







The search for new ligand libraries and leads continues in the drug discovery industry. Peptides 
and small molecule proteins have served as excellent ligands with applications in PPI inhibition, imaging, 
probing, and co-crystallization ligands. Along with these applications, peptides and small proteins have 
shown therapeutic effects, prompting research studies that focus on a class of peptide/protein-based drugs. 
We present a selection method that uses the mRNA display technique to discover MCPs and affibodies 
from a library consisting of sequence diversity up to 1012, specific to MtUGM. The RaPID system 
incorporated the FIT system to generate MCPs by spontaneous cyclization facilitated by the thioether bond 
formation between non-natural amino acid ClAcLF and first occurring Cys. The macrocyclic structures 
present many advantages as a drug-like molecule [88], thus, MCPs reported in this study can help provide 
insights on novel drug development. This technique of in vitro selection of MCP is not limited to 
discovering ligands for MtUGM, it can be adapted to select ligands for other target proteins with elucidated 
crystal structures. Affibodies are robust engineered small proteins that have been displayed using phage 
display [79-74], mRNA display of affibodies reported in this study is a novel approach. We successfully 
selected affibodies specific to MtUGM and hope to characterize them in future. Our study gives us an 
opportunity to explore applications of in vitro systems in discovering ligands from different type of 
compound libraries, in this case MCPs and affibodies, highlighting the dynamic nature and adaptability of 
the system. Together, the deep sequencing data generated and the mentioned display platform in this study 
will provide essential information for designing novel therapeutics, eventually assisting the development 
of new drug candidates for treating TB.  
4.6 Future Directions 
 
This project focussed on mRNA display as an in vitro selection platform for discovering 
peptide/protein-based ligands for the target MtUGM. Moving forward, the first thing to do next will be to 
test the MCPs for inhibition using the established HPAEC assay. By, coupling the inhibition assay with 
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GlfT2 (an enzyme that uses UDP-Galf as a substrate for galactosyltransferase activity for galactan 
synthesis) we can further validate our results. Our collaborator Dr. Christopher Hipolito and his student Ms. 
Nohara Goto together have discovered novel GlfT2-binding MCPs using the RaPID system. The discovered 
MCPs were then screened for inhibition by employing a novel biochemical assay. The assay is designed to 
measure fluorescence polarisation, by using a fluorescently labeled substrate; α-L-rhamnosyl-(1®3)-N-
acetyl-α-D-glucosamine, linked by diphosphate to Alexafluor 488 dye. This disaccharide will act as an 
acceptor for GlfT1 in the transfer of two successive Galf residues from UDP-Galf, generated in situ by 
MtUGM (from the conversion of UDP-Galp). Preliminary fluorescence polarization assays were performed 
by Kwan lab, Kd ～9µM was observed, however, the assay was not performed in replicates, thus, repeating 
it would be worthwhile. Performing an in vivo assay will be essential to see if the MCPs can pass through 
the cell membrane and maintain its activity. Our collaborator, Yossef Av-Gay has previously carried out 
cell death assays with Mtb with the discovered GlfT2-targeting MCPs to check the cytotoxicity, however, 
they were not active inside the cells. Thus, modifications on GlfT2-MCPs were made to increase cell 
penetration. Other assays like SPR (surface plasmon resonance), fluorescence polarisation binding assay 
(using fluorophore tagged peptide), and cell-based assays can be performed additionally to calculate IC50 
values.  
Crystallization techniques have previously revealed a structural basis for binding interactions as a 
valuable tool for target-specific ligands. Thus, further work will be to co-crystallize the MtUGM with the 
discovered ligands, both MCP and affibodies (in association with our collaborator, Kenneth Ng). This 
would provide information on the binding interactions made by these peptides. This can be used as a basis 
for designing novel drug-like molecules that inhibit this enzyme. Preliminary docking studies of discovered 
affibody by Thanasis Poullikas with MtUGM have revealed that it binds close to the active site, thus, it will 
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Figure A4. Recombinant protein expression of TEV protease (a) pRK793-MBP-His-TEV construct (b) SDS-
PAGE analysis of purified TEV. Lanes 1 to 8 contains fractions with desired proteins, bands at ~70 kDa 
corresponds to uncleaved MBP-His-TEV protein and bands at ~30 kDa corresponds to His-TEV. Lane 9- 
wash fraction where buffer was applied to elute non-desired proteins; lane 10- flow-through fractions 









Table A1. List of buffers. 
Name Components pH 
MtUGM Binding Buffer 50 mM, NaCl 200 mM, EDTA 1 mM 8 
MtUGM Elution Buffer 50 mM Tris, 200 mM NaCl, 1mM EDTA, 50 mM Maltose 8 
MtUGM Storage Buffer 25 mM Tris, 500 mM NaCl 7.5 
TGI Buffer 20 mM Tris, 250 mM NaCl, 20 mM Imidazole 7.5 
TEV Protease Elution Buffer 20 mM Tris, 250 mM NaCl, 220 mM Imidazole 7.5 
TEV Protease Storage Buffer 25 mM Tris, 500 mM NaCl 7.5 
MtUGM Selection Buffer 500 mM NaCl, 25 mM Tris-Cl, 0.005% TWEEN 20 7.5 
Affibody Binding Buffer 25 mM Tris, 10 mM imidazole, 500 mM NaCl 7.5 
Affibody Elution Buffer 25 mM Tris, 200 mM NaCl, 500 mM Imidazole 7.5 
Affibody Storage Buffer 50 mM Tris, 150 mM NaCl 7.5 
 
 







eFx-AmC-R18 A[2OMeC] CTAACGCTAATCCCCT 
AFR6-F GAAGTGCCATTCCGCCTGAC 
AFR6-R CACTGAGCCTCCACCTAGCC 
AFR6-insert-F TAATACGACTCACTATAGGG 
AFR6-insert-R GCTAGTTATTGCTCAGCGG 
T7-CH-F46 TAATACGACTCACTATAGGGTTGAACTTTAAGTAGGAGATATATCC 
CGS3an13-R39 TTTCCGCCCCCCGTCCTAGCTGCCGCTGCCGCTGCCGCA 
CGS3-CH-R24 TTTCCGCCCCCCGTCCTAAGACCC 
 
 
 
